A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy

This study has been terminated.
(See termination reason in detailed description.)
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01488877
First received: December 6, 2011
Last updated: September 24, 2013
Last verified: September 2013
Results First Received: July 18, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Basic Science
Condition: Type 2 Diabetic Nephropathy
Interventions: Drug: PF-03882845
Drug: Spironolactone
Other: placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Total 6 participants were enrolled in the study. Study was terminated early after partial completion of Cohort 1 (PF-03882845 3 milligram (mg)/placebo) and Cohort 4 (spironolactone 25 mg/placebo); Cohort 2 (PF-03882845 1 or 10 mg/placebo) and Cohort 3 (PF-03882845 1, 10 or 30 mg/placebo) were not enrolled.

Reporting Groups
  Description
PF-03882845 Placebo Placebo matched to PF-03882845 3 mg tablet in Cohort 1, orally once daily up to Day 14.
PF-03882845 3 mg PF-03882845 3 mg tablet in Cohort 1, orally once daily up to Day 14.
Spironolactone Placebo Similar-looking placebo matched to spironolactone 25 mg tablet in Cohort 4, orally once daily up to Day 14.

Participant Flow for 2 periods

Period 1:   Initial Randomization
    PF-03882845 Placebo     PF-03882845 3 mg     Spironolactone Placebo  
STARTED     1     5     0  
COMPLETED     1     5     0  
NOT COMPLETED     0     0     0  

Period 2:   Re-randomization
    PF-03882845 Placebo     PF-03882845 3 mg     Spironolactone Placebo  
STARTED     0     0     3 [1]
COMPLETED     0     0     3  
NOT COMPLETED     0     0     0  
[1] Three participants were re-randomized from PF-03882845 3 mg arm.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Entire Study Population All participants who were enrolled in this study.

Baseline Measures
    Entire Study Population  
Number of Participants  
[units: participants]
  6  
Age, Customized  
[units: participants]
 
less than (<) 18 years     0  
18 to 44 years     0  
45 to 64 years     6  
greater than or equal to (>=) 65 years     0  
Gender  
[units: participants]
 
Female     3  
Male     3  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change From Baseline in Serum Potassium at Day 8   [ Time Frame: Baseline, Day 7, 8 ]

2.  Primary:   Change From Baseline in Serum Potassium at Day 15   [ Time Frame: Baseline, Day 14, 15 ]

3.  Primary:   Number of Participants With Confirmed and Severe Hyperkalemia   [ Time Frame: Baseline up to Day 15 ]

4.  Secondary:   Plasma Pharmacokinetic (PK) Parameters   [ Time Frame: 0 (pre-dose), 2, 4, 6, 8, 10, 14, 24 hours post-dose on Day 1, 14 ]
  Hide Outcome Measure 4

Measure Type Secondary
Measure Title Plasma Pharmacokinetic (PK) Parameters
Measure Description PK parameters were to be evaluated at Day 1 and Day 14 (steady state). Maximum observed plasma concentration (Cmax), time to reach maximum observed plasma concentration (Tmax), area under the curve from time zero to end of dosing interval (AUCtau) were to be evaluated at both Day 1 and Day 14 (steady state). Minimum observed plasma trough concentration (Cmin), average plasma concentration (Cavg), apparent oral clearance (CL/F), apparent volume of distribution (Vz/F) were to be evaluated only at Day 14 (steady state). Observed accumulation ratio (Rac) was also planned to be analyzed.
Time Frame 0 (pre-dose), 2, 4, 6, 8, 10, 14, 24 hours post-dose on Day 1, 14  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Data for all pre-specified PK parameters were not analyzed because a decision was made to prematurely terminate the study.

Reporting Groups
  Description
PF-03882845 3 mg PF-03882845 3 mg tablet in Cohort 1, orally once daily up to Day 14.

Measured Values
    PF-03882845 3 mg  
Number of Participants Analyzed  
[units: participants]
  0  
Plasma Pharmacokinetic (PK) Parameters      

No statistical analysis provided for Plasma Pharmacokinetic (PK) Parameters



5.  Secondary:   Change From Baseline in Sitting Systolic and Diastolic Blood Pressure at Day 15   [ Time Frame: Day 1 (Baseline), 15 ]

6.  Secondary:   Change From Baseline in Sitting Pulse Rate at Day 15   [ Time Frame: Day 1 (Baseline), 15 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Study was terminated prematurely; this was based on a strategic decision by the sponsor to terminate further development of this compound for proposed indication. The study was not terminated for safety or lack of efficacy reasons.


  More Information